Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.39 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10209159 | 0.87 | S1PR1 (0.37) | SLC13A5ALDH1A1MCL1 | |
| SCHEMBL591389 | 0.83 | SLC13A5 (0.35) | SLC13A5 | |
| SCHEMBL590217 | 0.83 | SLC13A5 (0.34) | SLC13A5 | |
| SCHEMBL15925839 | 0.83 | SLC13A5 (0.34) | SLC13A5 | |
| SCHEMBL8500326 | 0.82 | FFAR1 (0.50) | LTB4RLTB4R2ALDH1A1MAPTMEN1 | |
| SCHEMBL589074 | 0.81 | SLC13A5 (0.34) | SLC13A5MAPTMEN1KMT2AFFAR1 | |
| SCHEMBL5399646 | 0.80 | MMP12 (0.44) | SLC13A5ALDH1A1FFAR1 | |
| SCHEMBL5035826 | 0.80 | ALDH1A1 (0.47) | ALDH1A1MAPT | |
| SCHEMBL5035787 | 0.80 | ALDH1A1 (0.47) | ALDH1A1MAPT | |
| SCHEMBL589077 | 0.76 | S1PR1 (0.36) | ALDH1A1MAPTFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2017257-B1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8114902-B2 | 2-aminobutanol compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8114902-B2 | 2-aminobutanol compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-2017257-A1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | ADRB2, ADRB1, ADRB3 | BRD4 202/4885RXRA 248/4885RXRB 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.